According to the Zhitong Finance App, Baiosetu-B (02315) issued an announcement. According to preliminary estimates by the company's finance department, the Group is expected to achieve operating revenue of RMB 936 million to RMB 946 million in the semi-annual year of 2026. Compared with the same period last year, it will increase RMB 315 million to RMB 325 million, an increase of 50.80% to 52.41% over the previous year.
Net profit attributable to owners of the parent company is estimated to be RMB236 million to RMB246 million in the semi-annual year of 2026. Compared with the same period last year, it will increase RMB188 million to RMB198 million, an increase of 391.87% to 412.71% year-on-year.
Net profit attributable to owners of the parent company after deducting non-recurring profit and loss is expected to be achieved in the first half of 2026 of RMB 192 million to RMB 202 million. Compared with the same period of the previous year, it will increase by RMB 164 million to RMB 174 million, an increase of 574.02% to 609.04% over the previous year.
The main reasons for the change in performance in the current period:
(1) As the biomedical industry enters a new stage of innovation leading industrial development, the company relies on forward-looking research and development, leading products and high-quality services, and a high-quality customer network covering the world's top pharmaceutical companies and leading biotechnology companies to fully unleash its competitive advantage and deeply embrace the business development opportunities brought about by increased industry prosperity. During the reporting period, the company's two major business lines achieved two-wheel drive and leapfrog collaboration, driving continuous rapid growth in revenue.
(2) Relying on the significant increase in the company's revenue scale and industry position, the scale effect of the company's production capacity and operation is showing at an accelerated pace. On this basis, combined with the continuous deepening of superimposed lean management, the company effectively reduced costs and increased efficiency, driving a further increase in overall gross margin, effectively reducing the cost ratio during the period, significantly increasing the company's profitability, and accelerating the release of large-scale profits.